Insulin-like growth factor binding proteins-2 and -4 enhance the migration of human CD34-/CD133+ hematopoietic stem and progenitor cells

International Journal of Molecular Medicine

Volumn 25, Issue 1, 2010, Pages 89-96

  Bartling, Babett ^a   Koch, Alexander ^a   Simm, Andreas ^a   Scheubel, Robert ^a   Silber, Rolf Edgar ^a   Santos, Alexander Navarrete ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

CD133; CD34; Hemaopoietic stem and progenitor cells; IGF binding proteins; Insulin like growth factor; Lung cancer; Migration

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 6;

ARTICLE; CANCER CELL; CELL MIGRATION; COCULTURE; CONTROLLED STUDY; FIBROBLAST; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LUNG CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 70549100927     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000317     Document Type: Article

References (51)

1. Franz CM, Jones GE and Ridley AJ: Cell migration in development and disease. Dev Cell 2: 153-158, 2002.
2. Guvakova MA: Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol 39: 890-909, 2007.
3. Denley A, Cosgrove LJ, Booker GW, et al: Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16: 421-439, 2005.
4. Firth SM and Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854, 2002.
5. Campbell PG, Durham SK, Hayes JD, et al: Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem 274: 30215-30221, 1999.
6. Jones JI, Gockerman A, Busby WH Jr, et al: Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha5beta1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 90: 10553-10557, 1993.
7. Daughaday WH and Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10: 68-91, 1989.
8. Yu H, Mistry J, Nicar MJ, et al: Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal 13: 166-172, 1999.
9. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003.
10. Renehan AG, Zwahlen M, Minder C, et al: Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353, 2004.
11. Takanami I, Imamuma T, Hashizume T, et al: Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol 61: 205-208, 1996.
12. Yu H, Spitz MR, Mistry J, et al: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151-156, 1999.
13. London SJ, Yuan JM, Travlos GS, et al: Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 94: 749-754, 2002.
14. Moorehead RA, Sanchez OH, Baldwin RM and Khokha R: Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene 22: 853-857, 2003.
15. Lyden D, Hattori K, Dias S, et al: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201, 2001.
16. Dome B, Dobos J, Tovari J, et al: Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A 73: 186-193, 2008.
17. Ahn GO and Brown JM: Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis 12: 159-164, 2009.
18. Gao D, Nolan D, McDonnell K, et al: Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 1796: 33-40, 2009.
19. Gao D, Nolan DJ, Mellick AS, et al: Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195-198, 2008.
20. Dome B, Timar J, Dobos J, et al: Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66: 7341-7347, 2006.
21. Hilbe W, Dirnhofer S, Oberwasserlechner F, et al: CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57: 965-969, 2004.
22. Silzle T, Randolph GJ, Kreutz M and Kunz-Schughart LA: The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer 108: 173-180, 2004.
23. Miraglia S, Godfrey W, Yin AH, et al: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013-5021, 1997.
24. Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997.
25. Gallacher L, Murdoch B, Wu DM, et al: Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood 95: 2813-2820, 2000.
26. Bhatia M: AC133 expression in human stem cells. Leukemia 15: 1685-1688, 2001.
27. Shi Q, Rafii S, Wu MH, et al: Evidence for circulating bone marrow-derived endothelial cells. Blood 92: 362-367, 1998.
28. Peichev M, Naiyer AJ, Pereira D, et al: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95: 952-958, 2000.
29. Hristov M, Erl W and Weber PC: Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 23: 1185-1189, 2003.
30. + endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 98: E20-E25, 2006.
31. Navarrete Santos A, Kahrstedt S, Nass N, et al: Evidences for age-related modulation of human hematopoietic progenitor cell proliferation. Exp Gerontol 43: 1033-1038, 2008.
32. Gammaitoni L, Bruno S, Sanavio F, et al: Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution. Exp Hematol 31: 261-270, 2003.
33. Krankel N, Adams V, Linke A, et al: Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol 25: 698-703, 2005.
34. Krsek M, Prazny M, Marek J, et al: The relationship between serum levels of insulin-like growth factor-I and its binding proteins and microvascular function in acromegalic patients. Growth Horm IGF Res 12: 54-59, 2002.
35. Yamaguchi T, Kanatani M, Yamauchi M, et al: Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif Tissue Int 78: 18-24, 2006.
36. Golub T, Slonim D, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
37. Lipshutz R, Fodor S, Gingeras T and Lockhart D: High density synthetic oligonucleotide arrays. Nat Genet 21: 20-24, 1999.
38. Urbich C and Dimmeler S: Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95: 343-353, 2004.
39. Bertolini F, Shaked Y, Mancuso P and Kerbel RS: The multi-faceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6: 835-845, 2006.
40. Falzon M, McMahon JB, Schuller HM and Boyd MR: Metabolic activation and cytotoxicity of 4-ipomeanol in human non-small cell lung cancer lines. Cancer Res 46: 3484-3489, 1986.
41. Silzle T, Kreutz M, Dobler MA, et al: Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol 33: 1311-1320, 2003.
42. Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514, 2008.
43. Pircher A, Kahler CM, Skvortsov S, et al: Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: A methodological challenge and an ongoing debate on the clinical relevance. Oncol Rep 19: 345-352, 2008.
44. Mroczko B, Szmitkowski M and Niklinski J: Stem cell factor and granulocyte-macrophage-colony stimulating factor as candidates for tumour markers for non-small-cell lung cancer. Clin Chem Lab Med 37: 959-962, 1999.
45. Enewold L, Mechanic LE, Bowman ED, et al: Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 18: 215-222, 2009.
46. Nakao-Hayashi J, Ito H, Kanayasu T, et al: Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis 92: 141-149, 1992.
47. Shigematsu S, Yamauchi K, Nakajima K, et al: IGF-1 regulates migration and angiogenesis of human endothelial cells. Endocr J 46: S59-S62, 1999.
48. Schutt BS, Langkamp M, Rauschnabel U, et al: Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32: 859-868, 2004.
49. Reeve JG, Brinkman A, Hughes S, et al: Expression of insulin-like growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines. J Natl Cancer Inst 84: 628-634, 1992.
50. Jaques G, Kiefer P, Schoneberger HJ, et al: Differential expression of insulin-like growth factor binding proteins in human non-small cell lung cancer cell lines. Eur J Cancer 28 (Suppl A): 1899-1904, 1992.
51. Fu P, Thompson JA and Bach LA: Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. J Biol Chem 282: 22298-22306, 2007.